Word of mouth

Oral semaglutide signals new phase for obesity treatment in the UK

The UK approval of once-daily oral Wegovy is a significant moment for obesity treatment. For the first time, patients can access semaglutide for chronic weight management without using an injection, widening the range of formulations available and potentially removing a genuine barrier for people with needle anxiety.

Yet the arrival of a tablet should not be mistaken for the arrival of an effortless treatment pathway.

Oral semaglutide may feel familiar, but its clinical use is unusually dependent on careful administration and patient understanding. That dependence stems from the formulation challenge. Enabling a peptide medicine, which would ordinarily be broken down in the gastrointestinal tract, to be absorbed orally is an impressive pharmaceutical achievement.

However, the conditions required to support that absorption also bring strict administration requirements and a different set of adherence challenges. For some patients, incorporating those requirements into an established routine may be straightforward. For others, existing medication schedules, shift work or caring responsibilities could make consistent use more difficult.

The weekly injection avoids many of those daily decisions, meaning the assumption that tablets are inherently more convenient will not hold for every patient.

Oral Wegovy therefore expands choice rather than establishing a universally simpler route of treatment. Its clinical value will depend on appropriate patient selection, clear counselling and ongoing monitoring, with formulation decisions based on how safely and consistently each patient is likely to use the medicine.

The evidence underpinning the drug’s real-world use is encouraging. In OASIS 4, people taking 25mg of oral semaglutide once a day lost an average of 13.6% of their body weight over 64 weeks, compared with 2.2% among those taking a placebo.

Stomach and digestive side effects were the most common, a result in line with the established safety profile of semaglutide. The question now is how closely these outcomes will be replicated in routine practice, where treatment persistence and correct administration will be less tightly controlled.

The expansion of formulation choice is clinically useful, but it also places greater emphasis on treatment selection. Oral and injectable semaglutide are not directly interchangeable, and differences in administration, absorption and dosing frequency mean the most appropriate option will vary between patients. This becomes particularly important when considering a switch from one formulation to another.

Achieving comparable outcomes in practice will depend on more than making the tablet available. Patients will need to be prescribed the formulation they are most likely to use safely and consistently, supported by clear counselling and ongoing monitoring.

This need for individualised treatment selection comes at a time of heightened regulatory scrutiny of pharmacy-led weight-management services.

In April 2026, the General Pharmaceutical Council called for stronger clinical governance, risk assessment, documentation and follow-up across the sector.

Oral semaglutide adds another consideration to those responsibilities. Prescribers must assess whether patients can realistically follow the administration regimen, investigate suboptimal response before changing treatment and document why any switch is clinically appropriate.

Dose strengths across oral and injectable semaglutide cannot be compared numerically. Oral semaglutide has lower and more variable bioavailability, and the effect of switching between formulations cannot easily be predicted. Although patients receiving 2.4mg injectable semaglutide once weekly can transition to the 25mg daily tablet, the availability of an approved pathway does not make switching a routine decision.

For a patient who is responding well to injectable treatment and tolerating it, convenience alone may not provide sufficient reason to change formulation. Any switch should follow a review of treatment response, adverse effects, concomitant medicines, patient preference and the likelihood that the oral regimen can be followed consistently.